Efficacy and safety of azithromycine versus amoxillineclavulanate in treatment of acute exacerbation of chronic bronchitis

Abstract EN

This study has been done to compare the efficacy, safety, and tolerability of azithromycin and amoxicillin-clavulanate in the treatment of patients with infectious exacerbation of chronic bronchitis(AECB).

This study was conducted at Al-Diwaniya Teaching Hospital and included 108 patients from 32 to 80 years of age.

Those patients were randomized to receive either azithromycin (500 mg / day for three days, n = 56) or amoxicillin-clavulanate (625 mg two tablets twice daily for seven days, n = 52).

The patients were evaluated at the study outset, on day 3-5, on day 7 and at long-term follow-up, day 28.

Based on the clinical evaluation of the signs and symptoms there were no differences between the groups treated with azithromycin or amoxicillin-clavulanate in terms of the percentages of cases in which the outcomes were classified as cure or improvement : 75% vs.

73.2% (p = >0.05) on day ten seven.

The results of the present study confirm the efficacy and tolerability of azithromycin for the outpatient treatment of episodes of infectious exacerbation of COPD.

In this context, it can be expected that the treatment with azithromycin will promote cure or clinical improvement in most patients, with acceptable toxicity and costs with no significant difference to the amoxicillin-clavulanate.